InterCure Proposes 5-to-1 Reverse Split to Avert Nasdaq Delisting
INCR sits 38% above its 52-week low of $0.68 on light trading volume (0.2× avg).
Summary
InterCure has called a shareholder vote on a 5-to-1 reverse stock split to regain compliance with Nasdaq's $1.00 minimum bid price rule, warning that failure to approve will likely result in delisting.
Key Events · Corporate Governance and Compliance · INCR
-
Reverse Split Proposal
Shareholders will vote on a 5-to-1 reverse stock split at an August 12, 2026 meeting, with a record date of July 29, 2026.
-
Nasdaq Compliance Deadline
The company received a minimum bid price deficiency notice on February 25, 2026, and has until August 24, 2026 to regain compliance or face delisting.
-
Delisting Risk
If the reverse split is not approved, the company warns its shares will likely be delisted to the over-the-counter market, reducing liquidity and institutional access.
-
Board Recommendation
The board unanimously recommends voting FOR the reverse split, stating it is in the best interests of the company and shareholders.
Analysis · INCR · Life Sciences
To address a Nasdaq deficiency notice received in February—after its shares traded below $1.00 for 30 consecutive business days—InterCure is asking shareholders to approve a 5-to-1 reverse stock split at an August 12 meeting. Without the reverse split, the stock will likely be delisted to the over-the-counter market, a move that would reduce liquidity, limit institutional investor access, and make future capital raises more difficult. The board unanimously recommends approval, framing it as essential to maintaining the Nasdaq listing that supports financing and shareholder liquidity.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INCR was trading at $0.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $55.7M. The 52-week trading range was $0.68 to $1.77. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.